| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/16/2008 | WO2008122769A2 Adenoviral vector encoding malaria antigen |
| 10/16/2008 | WO2008122551A2 Anti-epcam antibody and uses thereof |
| 10/16/2008 | WO2008122441A2 Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases |
| 10/16/2008 | WO2008122440A2 Remedy for the treatment of cardio-vascular diseases or disorders |
| 10/16/2008 | WO2008106116A3 Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| 10/16/2008 | WO2008103953A3 Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1) |
| 10/16/2008 | WO2008103409A3 Compositions of chloroquine coupled to antibodies and to other proteins with methods for their synthesis |
| 10/16/2008 | WO2008099178A3 Binding members for ige molecules |
| 10/16/2008 | WO2008094183A3 Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination |
| 10/16/2008 | WO2008089756A3 Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (gp2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis |
| 10/16/2008 | WO2008089438A3 A membrane receptor for retinol binding protein mediates cellular uptake of vitamin a, methods of use and compositions |
| 10/16/2008 | WO2008089394A3 Mycobacterium tuberculosis persistance genes |
| 10/16/2008 | WO2008086395A3 Anti-il-13 antibody formulations and uses thereof |
| 10/16/2008 | WO2008085987A3 Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display |
| 10/16/2008 | WO2008079372A9 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 10/16/2008 | WO2008079361A3 Cxcl13 binding proteins |
| 10/16/2008 | WO2008079270A3 Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis |
| 10/16/2008 | WO2008076560A3 Human monoclonal antibodies to btla and methods of use |
| 10/16/2008 | WO2008070332A3 Feline influenza vaccine and method of use |
| 10/16/2008 | WO2008063849A9 Multiple sclerosis therapy |
| 10/16/2008 | WO2008063586A3 Multicomponent vaccine |
| 10/16/2008 | WO2008063493A3 Compositions and methods related to toll-like receptor-3 |
| 10/16/2008 | WO2008060491A3 Anti-vegf treatment for radiation -induced vasculopathy |
| 10/16/2008 | WO2008057396A3 Canine lyme disease vaccine |
| 10/16/2008 | WO2008054481A3 Improved inactivated influenza virus compositions |
| 10/16/2008 | WO2008045373A3 Stable antibody formulations |
| 10/16/2008 | WO2008028946A3 Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| 10/16/2008 | WO2008021234A3 Methods and compositions for needleless delivery of particles |
| 10/16/2008 | WO2008014296A3 Composition and method for treatment of tumors |
| 10/16/2008 | WO2008013954A3 Tyrosine phosphorylation sites |
| 10/16/2008 | WO2008013953A3 Tyrosine phosphorylation sites |
| 10/16/2008 | WO2008013816A3 Tat-051 and methods of assessing and treating cancer |
| 10/16/2008 | WO2008011107A3 Antagonists of protease activated receptor-1 (par1) |
| 10/16/2008 | WO2007147090A3 Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| 10/16/2008 | WO2007134166A3 Real-time detection of influenza virus |
| 10/16/2008 | WO2007133373A3 TNF-α VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-α |
| 10/16/2008 | WO2007118084A3 Compositions and methods for treating polycystic kidney disease |
| 10/16/2008 | WO2007117505A3 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| 10/16/2008 | WO2007115230A3 A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells |
| 10/16/2008 | WO2007115059A3 Vaccine against streptococci |
| 10/16/2008 | WO2007109347A3 N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
| 10/16/2008 | WO2007094924A3 Human telomerase reverse transcriptase peptides |
| 10/16/2008 | WO2007014073A3 Concentrated protein lyophilates, methods, and uses |
| 10/16/2008 | WO2007012944A9 Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus |
| 10/16/2008 | WO2007005627A8 Tuberculosis antigen detection assays and vaccines |
| 10/16/2008 | WO2006138324A3 Treponema pallidum antigens for vaccine development and diagnostic tests |
| 10/16/2008 | WO2006081576A3 Immunologically active compositions |
| 10/16/2008 | WO2006078717A3 Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis |
| 10/16/2008 | WO2006060728A3 Methods and compositions involving lcrv proteins |
| 10/16/2008 | WO2005032463A3 Educated nkt cells and their uses in the treatment of immune-related disorders |
| 10/16/2008 | US20080254527 VON WILLEBRAND FACTOR (vWF) - CLEAVING PROTEASE |
| 10/16/2008 | US20080254506 Claudin polypeptides |
| 10/16/2008 | US20080254134 Controlled release antigen delivery, entrapped or encapsulated within a biodegradable polymer particles, which is a copolymer of glycolic acid and lactic acid; vaccination against B. pertussis, inducing T cell proliferation, treating respiratory system disorders |
| 10/16/2008 | US20080254132 stable antibodies dry powders consisting of monoclonal antibody and sucrose, threhalose, and mannitol; influenza virus instead of antibodies; viability, controlled particle size; storage stability, long shelf life without undue aggregation; used as therapeutics, nutrients, vaccines, pharmaceuticals |
| 10/16/2008 | US20080254129 Use of avian anti-methanogen antibodies for reduction of methane production |
| 10/16/2008 | US20080254105 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 10/16/2008 | US20080254095 Delivery device and method for forming the same |
| 10/16/2008 | US20080254085 Degradable Polymers Incorporating Gamma-Butyrolactone |
| 10/16/2008 | US20080254072 Method For Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens |
| 10/16/2008 | US20080254071 Homeopathic composition for alleviating allergy symptoms |
| 10/16/2008 | US20080254070 Bacterial secreted protein for use in generating vaccine for prevention of streptococcal infection; immunotherapy |
| 10/16/2008 | US20080254069 Vaccines for immunization against helicobacter |
| 10/16/2008 | US20080254068 Candida albicans CCM 8355; Candida glabrata CCM 8356; Candida krusei CCM 8357 and an immunomudulating Propionibacterium acnes strain; excipients, carriers |
| 10/16/2008 | US20080254067 Process for the Production of an Influenza Vaccine |
| 10/16/2008 | US20080254066 Emulsion comprising an aqueous phase, an oil phase, and a solvent and an immunogen |
| 10/16/2008 | US20080254065 Influenza Virus Vaccines |
| 10/16/2008 | US20080254064 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response |
| 10/16/2008 | US20080254063 Vaccines and Methods to Treat Canine influenza |
| 10/16/2008 | US20080254062 Double mutation causes a non-functional Type III secretion system and etiher no CyaA protein or a non-functional CyaA protein; respiratory system disorders |
| 10/16/2008 | US20080254061 Recombinant mycobacterium segmentis elicits HIV-1 envelope-specific CD8+ T cell responses; combination vaccines |
| 10/16/2008 | US20080254060 Attenuated viruses comprising modified NS1 genes, having an impaired ability to antagonize the cellular interferon response; decreased in vivo replication, virulence and increased attenuation; live cancer vaccines |
| 10/16/2008 | US20080254059 Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby |
| 10/16/2008 | US20080254058 Or surface-coupled proteins; a multivalent heterologous protein display vehicle; vaccines for infectious diseases, cancer, allergies, and autoimmune diseases |
| 10/16/2008 | US20080254057 Minimizing carrier-induced epitopic suppression in combination vaccines by minimizing the amount of unconjugated carrier protein; vaccines based on conjugated capsular saccharides from multiple serogroups |
| 10/16/2008 | US20080254053 Treating systemic inflammation via reducing c-reactive protein levels in the body |
| 10/16/2008 | US20080254052 Molecular differences between species of the m. tuberculosis complex |
| 10/16/2008 | US20080254051 Maintaining cytotoxic lymphocyte response to cell proliferation and/or viral infection via re-adminintering tumor antigen and/or viral particles; immunotherapy |
| 10/16/2008 | US20080254050 Immunotherapeutic comprising very small particles from neisserial outer memebrane protein and/or vascular endothelial growth factor for use in targeting a nd treating cell proliferative, inflammatory autoimmune and vision defects |
| 10/16/2008 | US20080254049 Composition for Treatment of Colds and Associated Symptoms |
| 10/16/2008 | US20080254048 He4 monoclonal antibodies and methods for their use |
| 10/16/2008 | US20080254047 Activation of Human Antigen-Presenting Cells Through CLEC-6 |
| 10/16/2008 | US20080254046 Method for the Delivery of Exogenous Antigens into the Mhc Class I Presentation Pathway of Cells |
| 10/16/2008 | US20080254045 Therapeutic mixture comprising a non-specific cluster of differentiation-1 (CD1d) complex which comprises beta 2-microglobulin and binds ceramide-like glycolipid antigens for use in treatment of autoimmune disorders |
| 10/16/2008 | US20080254044 Immunoglobulin fusion comprising cohesin-dockerin for use in targeting, treating and preventing cell proliferative disorders |
| 10/16/2008 | US20080254043 Drug For Treating Ischemic Disease |
| 10/16/2008 | US20080254042 Using prolactin-releasing peptide (PrRP) to identify modulators for prevention and treatment of nervous system, heart, hepatic and anxiety disorders |
| 10/16/2008 | US20080254041 Raising immunoglobulins with high specificity for environmental and/or commercial allergens |
| 10/16/2008 | US20080254040 Antagonists of receptors of enothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factors, HER2, IGF1R, HGFR or c-Kit, which is further an antagonist of a src tyrosine kinase family member, and chemotherapeutic agent; co-treatment with radiation therapy |
| 10/16/2008 | US20080254039 Prevention of Thrombus Formation and/or Stabilization |
| 10/16/2008 | US20080254038 Immunogen adherence inhibitor directed to lactobacillus organisms and method of making and using it |
| 10/16/2008 | US20080254037 Method of treating ischemia reperfusion injury by inhibing nkt cell activity |
| 10/16/2008 | US20080254036 Contains [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide (betrixaban) and antiplatelet agent for treatment of thrombosis; kits |
| 10/16/2008 | US20080254035 Expression vector comprising lipocalin gene sequences for use in prevention and treatment of cell proliferative, inflammatory, autoimmune and cardiovascular disorders |
| 10/16/2008 | US20080254034 Microbial membrane protein for use in diagnosis, prevention and treatment of gramnegative bacterial infection |
| 10/16/2008 | US20080254033 Pharmaceutical Compositions Containing Antagonists to Lrp4, Lrp8 or Megalin for Treatment of Diseases |
| 10/16/2008 | US20080254032 Colony stimulating bfcator specific monoclonal antibody for use in diagnosis, prevention and treatment of infcetion, cell proliferative, inflammatory, autoimmune, arthritic, skin, respiratory and nervous system disorders |
| 10/16/2008 | US20080254031 Nucleotide sequences coding tumor antigens for use as diagnostic tool in detection and staging of cell proliferative disorders |
| 10/16/2008 | US20080254030 Using B cell survival factor (BAFF) agonist as therapeutic in treatment of asthma |
| 10/16/2008 | US20080254029 Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis |
| 10/16/2008 | US20080254028 Caspase-8 interacting polypeptide (Cari) for use in identifying modulators for prevention and treatment of autoimmune, inflammatory, connective tissue and liver disorders |